Atypical / Dysplastic Naevus

^[1]

Meet the patient

A 24-year-old man presents for a "mole check". His back carries more than 80 naevi of varying size and colour, and one on his left scapula is darker, larger, and more irregular than the rest — the outlier among his own moles. His father was treated for melanoma at 45 and died of pancreatic cancer at 58.^[1]

The two questions that decide his lifetime plan are the two every atypical-naevus stem turns on: is this lesion melanoma or just one of many atypical naevi? (the ugly duckling and dermoscopy decide it) and does this patient carry a familial syndrome that changes his surveillance forever? (FAMMM, CDKN2A, and pancreatic screening). Hold those two and the whole topic lines up.^[1][3]

A marker, not a precursor — the concept that runs the topic

The single most important idea on this page is that an atypical naevus is a field marker of melanoma risk, not a lesion that must be cut out. Most melanomas arise de novo from uninvolved skin, not from a pre-existing naevus, so prophylactically excising every atypical naevus does not reduce melanoma mortality — it only generates scarring, cost, and anxiety. The job is to detect melanoma early through surveillance, not to prevent it by excision.^[1][4]

Atypical naevi sit on a spectrum from ordinary benign naevi to melanoma. Their presence signals a higher chance of melanoma developing somewhere on the skin — within a pre-existing naevus or, more often, de novo. That is why the management is risk-stratified observation with a low threshold to biopsy change.^[1]

What "atypical" and "dysplastic" actually mean

"Atypical" describes the clinical appearance; "dysplastic" describes the histology — and the two do not always agree. A lesion that looks clinically atypical may be histologically banal, and a histologically dysplastic naevus may look clinically ordinary. Management must integrate both, not rely on one.^[4]

The historical names matter for viva. Clark naevus honours Wallace Clark, who linked irregular naevi to melanoma risk. The B-K mole (initials of two affected families) is now subsumed into FAMMM syndrome — familial atypical multiple mole melanoma. Know the gene: CDKN2A, encoding the tumour suppressors p16INK4a and p14ARF.^[1][3]

Classification — by clinical context, which is what sets risk

Risk is driven by clinical context, so classify by context: sporadic, atypical mole syndrome, or FAMMM. The relative melanoma risk climbs from about two-fold to more than fifty-fold across the three groups, and that climb is what sets the surveillance interval.^[1][2]

^[1]

Histologically, dysplastic naevi are graded mild, moderate, or severe by the degree of architectural disorder and cytological atypia. The grading has a practical consequence: severely dysplastic naevi with positive margins are usually re-excised, whereas mild or moderate lesions with positive margins are often observed.^[5][8][9]

Epidemiology — fair skin, sun, and the naevus count

About 2 to 8 percent of the general population carry at least one clinically atypical naevus. Prevalence is higher in fair-skinned people who burn rather than tan, and in populations with high cumulative sun exposure. Atypical naevi appear from childhood and adolescence and may increase through early adulthood; they are uncommon in darker phototypes.^[2]

The risk factors to run on autopilot are fair skin with light eye and hair colour, intermittent high-dose UV exposure and childhood sunburns (which drive new naevi and atypia), a family history of melanoma, a high total naevus count (more than 50 common naevi is itself a risk factor), and immunosuppression (transplant recipients develop more naevi and more melanoma). The naevus count and the atypical-naevus count are independent risk factors: more than 100 common naevi carries far more risk than fewer than 15, and even a single atypical naevus roughly doubles risk.^[1]

^[1]

FAMMM syndrome is rare and autosomal dominant, most often from germline CDKN2A mutations. Penetrance is incomplete but carriers carry a markedly elevated lifetime melanoma risk and an increased pancreatic cancer risk — which is why FAMMM surveillance is about more than skin.^[3]

Pathophysiology — two questions on the slide, and why most naevi stay benign

The histological diagnosis asks two questions: is the architecture disordered, and are the melanocytes atypical? Both must be answered for a dysplastic naevus, and the boundary between severe dysplasia and melanoma in situ is not always sharp — experienced dermatopathologists can disagree on the same section.^[4][5]

Architectural disorder means lentiginous or junctional proliferation of melanocytes along the basal layer (single cells or small nests rather than the regular nests of a benign naevus), bridging of rete ridges by melanocytic nests, shouldering (the junctional component extending beyond the deral component), lamellar or concentric fibrosis in the papillary dermis, a chronic inflammatory infiltrate, and variable pigmentation. Cytological atypia means enlarged, hyperchromatic, pleomorphic nuclei, sometimes with prominent nucleoli, graded mild, moderate, or severe.^[1][5]

BRAF, senescence, and the barrier that usually holds

At the molecular level, most sporadic atypical naevi carry activating BRAF mutations (classically BRAF V600E) — yet most never become melanoma, because oncogene-induced senescence arrests further growth. That senescence is mediated by p16INK4a, encoded by CDKN2A. In FAMMM syndrome one CDKN2A copy is defective from birth, which lowers the threshold for malignant progression when a second hit lands. NRAS and NF1 mutations are less common drivers; progression to melanoma needs additional events such as CDKN2A inactivation, PTEN loss, or TERT promoter activation.^[1][3]

The precursor-versus-marker controversy — and why it changes management

For decades, pathologists and clinicians argued whether dysplastic naevi are true melanoma precursors or merely risk markers. The modern consensus is primarily risk marker, with the caveat that severely dysplastic lesions may occasionally be melanoma in situ or early invasive melanoma that is hard to distinguish histologically. That uncertainty is exactly why severely dysplastic naevi with positive margins are re-excised while mild-to-moderate lesions are observed.^[2][4]

Clinical presentation — ABCDE and the ugly duckling

The clinical features of an atypical naevus are the ABCDE criteria, first described for melanoma screening and applied to atypical naevi:^[7]

• A — Asymmetry: one half does not match the other.
• B — Border irregularity: notched, scalloped, or indistinct edges.
• C — Colour variegation: two or more colours — tan, brown, black, red, white, blue — within one lesion.
• D — Diameter: usually larger than 5 mm, though diameter alone is a poor discriminator.
• E — Evolution: any change in size, shape, colour, elevation, surface, or symptoms such as bleeding or itching — often the most important clue.^[1]

Atypical naevi are often 5 to 12 mm or larger, macular or papular, sometimes with a target or fried-egg appearance — a raised pink or tan centre with a darker flat peripheral rim. Distribution favours the trunk and extremities and often spares the face and acral sites; multiple lesions sharing some irregularity but differing in size and colour typify atypical mole syndrome.^[1]

The ugly duckling sign is the single most useful concept in a patient with many naevi. Each person has a characteristic naevus pattern; the lesion that looks different from that patient's own others — the outlier — is the one most likely to be melanoma. In AMS or FAMMM, applying ABCDE to every lesion is overwhelming and insensitive; the ugly duckling cuts through it.^[1]

^[1]

Atypical faces — children, pregnancy, the immunosuppressed, the elderly

Children: atypical naevi may appear around puberty. Childhood melanoma is rare but is associated with FAMMM syndrome, congenital naevi, and immunosuppression; any rapidly changing or unusually large lesion in a child warrants referral and biopsy.^[6]

Pregnancy: naevi may darken or enlarge under hormonal change, usually benign; biopsy is reserved for lesions with suspicious clinical or dermoscopic change. Immunosuppression: transplant recipients and chronic immunosuppressed patients develop more naevi and more melanoma; surveillance tightens. The elderly: a new or changing pigmented lesion carries a higher pre-test probability of melanoma — lower the threshold for biopsy, and remember that lentigo maligna melanoma can mimic a solar lentigo on sun-damaged skin.^[1]

Differential — the mimics, each with a dermoscopic clue

The main diagnostic challenge is separating an atypical naevus from melanoma, because both can show asymmetry, border irregularity, colour variegation, and a diameter over 5 mm. The discriminator is dermoscopy and, when in doubt, excisional biopsy.^[1]

^[1]

Assessment — total body photography, dermoscopy, and the ugly duckling

Examine the whole skin in good light with a dermatoscope — scalp, nails, palms, soles, genitalia, and mucous membranes — because melanoma risk is a field effect and a new primary can arise anywhere. The toolkit is total body photography as a baseline for comparison, dermoscopy for subsurface structure, and sequential digital dermoscopy for individual lesions tracked over months to years.^[1]

The ugly duckling sign — find the lesion that differs from the patient's own pattern — is more sensitive than applying ABCDE to every lesion when the naevus count is high. At the bedside ask about change in any lesion, symptoms (itching, bleeding, tenderness), personal or family melanoma history, sun exposure and burning tendency, and immunosuppression. Document the naevus count, the atypical-naevus count, and any suspicious lesion with a photograph or dermoscopic image.^[1]

Investigations — dermoscopy first, then biopsy the right way

Dermoscopy is the most important office investigation. An atypical naevus shows asymmetry of colour and structure, an atypical or irregular pigment network (thickened, widened, abruptly ending lines), irregular globules, hyperpigmented or structureless zones, and a peripheral faint or negative pigment network. Melanoma-specific features — blue-white veil, atypical vessels, regression structures, irregular streaks or pseudopods, atypical blotches, ulceration, and marked asymmetry with multiple colours — shift the lesion from "atypical naevus" to "suspicious for melanoma" and mandate excisional biopsy.^[7]

Excisional biopsy with a narrow margin (1 to 3 mm) is preferred for any lesion suspicious for melanoma, because it allows full histological assessment including Breslow thickness. Shave or punch biopsy is avoided when melanoma is in the differential — partial sampling can miss the invasive component and preclude accurate Breslow measurement. Reflectance confocal microscopy is an adjunct when dermoscopy is inconclusive but does not replace histology.^[8]

The histology report must grade dysplasia (mild, moderate, severe — though interobserver agreement is only moderate and some centres now use a binary low-grade versus high-grade system) and comment on melanoma-warning features: pagetoid spread above the basal layer, dermal mitoses, asymmetrical dermal nests, ulceration, or lymphovascular invasion. Any of those tips the diagnosis to melanoma.^[1]

Genetic counselling and CDKN2A testing belong in families with multiple melanomas, especially with early onset or pancreatic cancer, and are offered to adults after formal counselling.^[3]

Management — observe most, biopsy change, re-excise severe

The mantra: do not prophylactically excise, observe with photography, biopsy only change, re-excise severe dysplasia with positive margins. The majority of atypical naevi need surveillance, not surgery.^[1]

Why observation, not prophylaxis

A landmark concept: the presence of atypical naevi reflects increased field cancerisation across the entire skin, not a high per-lesion risk. Removing every atypical naevus would not eliminate the risk of melanoma arising de novo and would cause substantial morbidity. The goal is early detection of melanoma, and total body photography with sequential digital dermoscopy does that far better than mass excision.^[1][4]

Risk-stratified surveillance

Histology-driven management — the grade and the margin

The management of a biopsy-proven dysplastic naevus turns on grade and margin.^[8][9][10]

Mild dysplasia, clear margins: observe. Even positive margins are usually observed if there is no residual clinical pigment and no clinical suspicion. Moderate dysplasia, clear margins: observe; positive margins without residual pigment may also be observed, though re-excision can be considered in high-risk patients or if clinical concern persists. Severe dysplasia, any margins: re-excise to clear margins, typically 2 to 5 mm, because the distinction from early melanoma can be difficult.^[8]

Clinical suspicion trumps histology. A lesion that looks suspicious for melanoma but returns as dysplastic naevus should be re-excised or re-biopsied — partial sampling may have missed melanoma. Excision technique is a full-thickness elliptical excision with a narrow margin, oriented so the pathologist can assess margins; shave or punch is avoided when melanoma is in the differential.^[8][9]

^{[1] [1] [1]}

Sun protection, self-examination, and honest reassurance

Sun protection is non-negotiable: broad-spectrum sunscreen (SPF 30 or higher), protective clothing, wide-brimmed hats, and avoidance of peak UV between 10 am and 4 pm. Teach monthly self-examination in good light with a hand mirror, looking for the ugly duckling and any changing, itching, bleeding, or non-healing lesion. Prompt presentation of any change is the single most important behaviour for early melanoma detection.^[1]

Address anxiety honestly. Patients with multiple atypical naevi or FAMMM are often frightened; a structured surveillance plan, baseline photography, and clear education reduce anxiety and improve adherence. The risk is increased, but most lesions are benign, and early melanoma is highly curable.^[1]

Specific scenarios — sporadic, AMS, FAMMM, pregnancy, children

Sporadic atypical naevus carries modestly increased risk; management is reassurance, education, surveillance, and biopsy of changing lesions. Atypical mole syndrome (more than 50 naevi, at least 5 atypical, no family history) carries roughly 10-fold risk and earns total body photography, sequential digital dermoscopy, and regular dermatology review — never mass excision.^[1]

FAMMM syndrome earns intensive melanoma surveillance every 3 to 6 months from early adulthood, total body photography and sequential digital dermoscopy at each visit, genetic counselling and CDKN2A testing where appropriate, and pancreatic cancer screening with MRI or MRCP starting around age 40 to 50 or 10 years before the earliest family pancreatic cancer. Counsel families on incomplete CDKN2A penetrance: not every carrier develops melanoma, but the lifetime risk justifies intensive surveillance.^[1][3]

Pregnancy allows physiological darkening and enlargement; dermoscopy and biopsy only for suspicious change; routine prophylactic excision is not indicated. Children: atypical naevi are usually benign, but rapidly changing, ulcerated, or unusually large lesions are biopsied or referred urgently, and FAMMM families are offered genetic counselling.^[6]

Pitfalls — pseudo-melanoma, sampling error, and the overloaded mole count

Pseudo-melanoma (recurrent naevus) — a partially biopsied or traumatised naevus regrows within a scar with atypical histology that mimics melanoma. This is one reason to avoid partial biopsy of suspicious lesions and one reason some clinicians re-excise dysplastic naevi with positive margins.^[8]

Sampling error — a shave or punch may miss the most atypical area or the invasive component. If clinical suspicion for melanoma is high, excisional biopsy is preferred and must be full-thickness with the entire lesion and a narrow margin. Over-diagnosis and over-treatment — the word "dysplastic" alarms patients and clinicians alike; prophylactic excision of all atypical naevi is not recommended and does not reduce melanoma mortality.^[1]

Interobserver variability — histological grading is not perfectly reproducible; the same lesion may be called mild, moderate, or severe by different pathologists. Integrate clinical and histological findings; do not lean on the grade alone. And in the heavily naevus-burdened patient, do not rely on ABCDE alone — a melanoma can hide among hundreds of naevi. The ugly duckling and baseline photography are the defence.^[1]

Prognosis — per-lesion risk is low; patient risk is what matters

Atypical naevi are benign. The concern is their association with melanoma risk, not a high per-lesion risk of transformation. The risk that any single atypical naevus becomes melanoma is very low, because most melanomas arise de novo; removing every atypical naevus would not eliminate melanoma risk. What matters is the patient-level lifetime risk, elevated in AMS and markedly elevated in FAMMM.^[1]

Once a dysplastic naevus is fully excised with clear margins, that lesion is cured; the patient remains at increased risk of future melanoma elsewhere and needs continued surveillance. The strongest predictors of future melanoma are a personal history of melanoma, a family history of melanoma, the total naevus count, the atypical-naevus count, and a CDKN2A mutation. Most patients are managed in dermatology or pigmented lesion clinics; FAMMM patients may need multidisciplinary care spanning dermatology, genetics, and gastroenterology for pancreatic screening.^[1]

Evidence, guidelines, and where regions differ

The landmark evidence is the 1992 NIH consensus that defined the dysplastic naevus and FAMMM, the 2015 Pigmented Lesion Subcommittee consensus that supported observation for mild and moderate dysplasia with clear margins and selective observation for moderate dysplasia with positive margins (re-excise severe),^[8] Fleming and colleagues (2016) confirming selective observation for mild and moderate dysplasia with positive margins,^[9] and Adamson (2018) concluding observation is appropriate for moderate dysplasia with positive margins when no residual clinical pigment remains.^[10] Newton-Bishop (2020) underpins the CDKN2A counselling and pancreatic risk.^[3]

The open controversies are terminology (some prefer "naevus with architectural disorder and cytological atypia" or a binary low- versus high-grade system over mild/moderate/severe),^[2] the precursor-versus-marker question (practically resolved toward marker), re-excision thresholds (trending toward less surgery for mild-to-moderate dysplasia), and the optimal modality and age to start pancreatic screening in CDKN2A carriers. Regional practice converges on the PLS consensus; differences are mainly in access to total body photography, sequential digital dermoscopy, and genetics services.^[1]

Exam pearls

^[1]

Ward-round test

A biopsy returns as moderately dysplastic naevus with positive margins but no residual clinical pigment. What do you do?ShowHide

Observe. The 2015 Pigmented Lesion Subcommittee consensus and subsequent data support observation for mildly and moderately dysplastic naevi with positive margins when there is no residual clinical pigment and no clinical suspicion for melanoma. Severely dysplastic naevi, however, are re-excised. Document, photograph, and schedule surveillance.

^{[1] [8] [10]}

A 24-year-old with more than 80 naevi has a darker, irregular outlier on his scapula, and his father had melanoma and pancreatic cancer. What syndrome, what gene, and what added screening?ShowHide

FAMMM syndrome — familial atypical multiple mole melanoma — most often from a germline CDKN2A mutation. Beyond intensive dermatology surveillance every 3 to 6 months with total body photography and sequential digital dermoscopy, offer genetic counselling and pancreatic cancer screening with MRI or MRCP from around age 40 to 50 or 10 years before the earliest family pancreatic cancer.

^[3]

A clinician plans to excise every atypical naevus on a patient with atypical mole syndrome to prevent melanoma. Why is this wrong?ShowHide

Because atypical naevi are primarily risk markers, not precursors, and most melanomas arise de novo. Mass excision does not reduce melanoma mortality and causes scarring, cost, and anxiety. The correct strategy is total body photography, sequential digital dermoscopy, regular dermatology review, and biopsy only of changing or ugly-duckling lesions.

^[1]

A shave biopsy of a suspicious pigmented lesion returns dysplastic naevus, but the lesion looked ugly. What is the trap?ShowHide

Sampling error and pseudo-melanoma. A shave may miss the invasive component of melanoma or the most atypical area, and a partially biopsied naevus can recur in the scar mimicking melanoma. Clinical suspicion trumps histology: if the lesion looked suspicious, re-excise or re-biopsy with a full-thickness excisional technique so the pathologist can assess margins and Breslow thickness.

^[8]

References10ShowHide

1. [1]Zhang Y, Ostrowski SM, Fisher DE. Nevi and Melanoma Hematol Oncol Clin North Am, 2024.PMID 38880666
2. [2]Drozdowski R, Spaccarelli N, Peters MS, et al. Dysplastic nevus part I: Historical perspective, classification, and epidemiology J Am Acad Dermatol, 2023.PMID 36038073
3. [3]Newton-Bishop J, Bishop DT, Harland M. Melanoma Genomics Acta Derm Venereol, 2020.PMID 32346746
4. [4]Friedman RJ, Farber MJ, Warycha MA, et al. The dysplastic nevus Clin Dermatol, 2009.PMID 19095156
5. [5]Bierhoff E. [Dysplastic melanocytic nevus] Pathologe, 2015.PMID 25591417
6. [6]Jen M, Murphy M, Grant-Kels JM. Childhood melanoma Clin Dermatol, 2009.PMID 19880040
7. [7]Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria JAMA, 2004.PMID 15585738
8. [8]Kim CC, Swetter SM, Curiel-Lewandrowski C, et al. Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement JAMA Dermatol, 2015.PMID 25409291
9. [9]Fleming NH, Egbert BM, Kim J, et al. Reexamining the Threshold for Reexcision of Histologically Transected Dysplastic Nevi JAMA Dermatol, 2016.PMID 27542070
10. [10]Adamson AS. Observation of Moderately Dysplastic Nevi With Positive Margins: Are We There Yet? JAMA Dermatol, 2018.PMID 30304351